Congenital amegakaryocytic thrombocytopenia (CAMT) is an inherited disorder characterized at birth by thrombocytopenia with reduced megakaryocytes, which evolves into generalized bone marrow aplasia during childhood. Although CAMT is genetically heterogeneous, mutations of MPL, the gene encoding for the receptor of thrombopoietin (THPO), are the only known disease-causing alterations. We identified a family with three children affected with CAMT caused by a homozygous mutation (p.R119C) of the THPO gene. Functional studies showed that p.R119C affects not only ability of the cytokine to stimulate MPL but also its release, which is consistent with the relatively low serum THPO levels measured in patients. In all the three affected children, treatment with the THPO-mimetic romiplostim induced trilineage hematological responses, remission of bleeding and infections, and transfusion independence, which were maintained after up to 6.5 years of observation. Recognizing patients with THPO mutations among those with juvenile bone marrow failure is essential to provide them with appropriate substitutive therapy and prevent the use of invasive and unnecessary treatments, such as hematopoietic stem cell transplantation or immunosuppression.

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim

Savoia, Anna
2018-01-01

Abstract

Congenital amegakaryocytic thrombocytopenia (CAMT) is an inherited disorder characterized at birth by thrombocytopenia with reduced megakaryocytes, which evolves into generalized bone marrow aplasia during childhood. Although CAMT is genetically heterogeneous, mutations of MPL, the gene encoding for the receptor of thrombopoietin (THPO), are the only known disease-causing alterations. We identified a family with three children affected with CAMT caused by a homozygous mutation (p.R119C) of the THPO gene. Functional studies showed that p.R119C affects not only ability of the cytokine to stimulate MPL but also its release, which is consistent with the relatively low serum THPO levels measured in patients. In all the three affected children, treatment with the THPO-mimetic romiplostim induced trilineage hematological responses, remission of bleeding and infections, and transfusion independence, which were maintained after up to 6.5 years of observation. Recognizing patients with THPO mutations among those with juvenile bone marrow failure is essential to provide them with appropriate substitutive therapy and prevent the use of invasive and unnecessary treatments, such as hematopoietic stem cell transplantation or immunosuppression.
2018
congenital amegakaryocytic thrombocytopenia
MPL
mutation
romiplostim
thrombopoietin
Molecular Medicine
File in questo prodotto:
File Dimensione Formato  
63.full.pdf

non disponibili

Dimensione 757.46 kB
Formato Adobe PDF
757.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
EMMM-10-63-s001.pdf

non disponibili

Dimensione 286.2 kB
Formato Adobe PDF
286.2 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
EMMM-10-63-s002.pdf

non disponibili

Dimensione 433.63 kB
Formato Adobe PDF
433.63 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
EMMM-10-63-s008.pdf

non disponibili

Dimensione 372.88 kB
Formato Adobe PDF
372.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1064375
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 40
social impact